Axogen VP Doris Quackenbush Form 3 Filing - Equity Holdings and Awards

This Form 3 filing reports the initial statement of beneficial ownership for Doris Quackenbush, Vice President of Sales at Axogen, Inc. (AXGN). The filing discloses her ownership of 96,294 shares of common stock as of May 1, 2026. Additionally, the filing details several equity awards including restricted stock units and employee stock options. The restricted stock units total 65,750 shares with vesting schedules extending through 2030, while the stock options cover 43,547 shares with exercise prices ranging from $8.20 to $11.88 and expiration dates through 2033. The awards follow standard vesting schedules with 50% vesting after 24 months and additional portions vesting periodically thereafter. The filing was signed by attorney-in-fact Marc Began on behalf of Doris Quackenbush.